Multiple Myeloma   

For example, per the IMROZ trial methodology, Isatuximab dosing does not change to monthly dosing until >18 cycles which can impact patient QoL and...

Or can we omit it in older patients given efficacy of these regimens? Is transplant-eligibility still an important distinction up front given options ...

Do the IMROZ and BENEFIT trials inform choice? In IMROZ, the high-risk population received only revlimid/dexamethasone maintenance. Should they have g...